Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No clinically important abnormal physical findings.~* No clinically significant laboratory abnormalities.~* Normal (or abnormal but not clinically significant) ECG measurements.~* Body mass index between 18.0 and 32.0 kg/m2.~* Normal (or abnormal but not clinically significant) blood pressure and pulse rate measurements. methylxanthine-containing beverages or food~* Non-smoker~Exclusion Criteria:~* Received any investigational drug within 8 weeks before administration of the first dose of the study drug~* Female who is pregnant, has a positive pregnancy test, or is breastfeeding.~* Positive test result for amphetamines, barbiturates, benzodiazepines, cocaine metabolites, opiates, cannabinoids, methylenedioxymethamphetamine, cotinine, or alcohol in urine at Screening or Day -1.~* Positive screening test for hepatitis B surface antigen, hepatitis C, and/or human immunodeficiency virus antibodies.~* Any surgical or medical condition that, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism, or excretion of the drug.~* Used any medication (prescription or over-the-counter, including health supplements and herbal remedies, with the exception of acetaminophen, as defined in exclusion number 8) within 2 weeks (4 weeks for drugs or substances known to inhibit or induce CYP enzymes and/or P-gp including St. John's wort \[Hypericum perforatum\]) or 5 half-lives (whichever is longer) before the first dose of study drug.~* Used an oral or IV antibiotic within 4 weeks of administration of the first dose of the study drug.~* Routinely or chronically used more than 2 g of acetaminophen daily.~* Performed strenuous activity, sunbathing, and/or contact sports within 96 hours (4 days) before entry into the clinical study site on Day -1, and for the duration of the study.~* Donated or lost greater than 400 mL of blood in the 30 days before administration of the first dose of the study drug.~* History of clinically significant GI disease, or gastroenteritis (vomiting or diarrhea) or any history of GI bleeding (excluding bleeding from hemorrhoids)~* History of any significant drug allergy~* History of any drug or alcohol abuse in the past 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Midazolam/Delafloxacin (Type: EXPERIMENTAL): Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).